Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0
|
作者：
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
机构：
[1] Hospital Ramón y Cajal,Servicio de Oncología Médica
[2] University Hospital of Wuerzburg,Department of Nuclear Medicine
[3] Central Hospital of Augsburg,Department of Nuclear Medicine
[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities
[5] Royal Marsden Hospital,Thyroid Unit
[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute
[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute
[9] Odense University Hospital,Department of Oncology, Clinical Research Unit
[10] Hospital Ramón y Cajal,Cardiology Service
[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit
[12] Autonomous University of Barcelona,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 966
页数：21
相关论文
共 50 条
  • [31] Treatment of advanced medullary thyroid cancer
    Smit J.
    Thyroid Research, 6 (Suppl 1)
  • [32] Management of treatment-related toxicities in advanced medullary thyroid cancer
    Brose, Marcia S.
    Bible, Keith C.
    Chow, Laura Q. M.
    Gilbert, Jill
    Grande, Carolyn
    Worden, Francis
    Haddad, Robert
    CANCER TREATMENT REVIEWS, 2018, 66 : 64 - 73
  • [33] Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
    Werner, Rudolf A.
    Schmid, Jan-Stefan
    Higuchi, Takahiro
    Javadi, Mehrbod S.
    Rowe, Steven P.
    Maerkl, Bruno
    Aulmann, Christoph
    Fassnacht, Martin
    Kroiss, Matthias
    Reiners, Christoph
    Buck, Andreas K.
    Kreissl, Michael C.
    Lapa, Constantin
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 756 - 761
  • [34] Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
    Fallahi, Poupak
    Ferrari, Silvia Martina
    Elia, Giusy
    Ragusa, Francesca
    Paparo, Sabrina Rosaria
    Ruffilli, Ilaria
    Patrizio, Armando
    Materazzi, Gabriele
    Antonelli, Alessandro
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7893 - 7907
  • [35] Management of medullary carcinoma of the thyroid: a review
    Jayasinghe, Ravindri
    Basnayake, Oshan
    Jayarajah, Umesh
    Seneviratne, Sanjeewa
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (07)
  • [36] Systemic treatment and management approaches for medullary thyroid cancer
    Ernani, Vinicius
    Kumar, Mukesh
    Chen, Amy Y.
    Owonikoko, Taofeek K.
    CANCER TREATMENT REVIEWS, 2016, 50 : 89 - 98
  • [37] Surgical aspects and controversies in the management of medullary thyroid cancer
    Green, Katerina
    Hintze, Justin
    O'Neill, James Paul
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (06) : 2461 - 2466
  • [38] Current management of medullary thyroid cancer
    Sippel, Rebecca S.
    Kunnimalaiyaan, Muthusamy
    Chen, Herbert
    ONCOLOGIST, 2008, 13 (05) : 539 - 547
  • [39] The Surgical Management of Medullary Thyroid Cancer
    Dackiw, Alan P. B.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2010, 43 (02) : 365 - +
  • [40] Surgical aspects and controversies in the management of medullary thyroid cancer
    Katerina Green
    Justin Hintze
    James Paul O’Neill
    Irish Journal of Medical Science (1971 -), 2022, 191 : 2461 - 2466
12345